Pelvic Inflammatory Disease (PID) News and Research

RSS

First evidence of human DNA fragment in bacterial genome

If a human cell and a bacterial cell met at a speed-dating event, they would never be expected to exchange phone numbers, much less genetic material. In more scientific terms, a direct transfer of DNA has never been recorded from humans to bacteria.

14 Feb 2011

Merck announces publication of GARDASIL pivotal Phase III study data in NEJM

Merck announced today that data from the pivotal Phase III study with GARDASIL in males were published in the February 3 issue of the New England Journal of Medicine.

3 Feb 2011

Study compares treatment cost of PID hospitalizations, ER care for teen girls

Hospitalizing teen girls with pelvic inflammatory disease costs six times as much as treating them in the emergency room, and up to 12 times more than treating them in an outpatient clinic, according to a small study conducted at the Johns Hopkins Children's Center.

6 Jan 2011

Merck announces FDA approval for GARDASIL against HPV-related anal cancer

Merck, known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has approved GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant] for the prevention of anal cancer caused by human papillomavirus (HPV) types 16 and 18 and for the prevention of anal intraepithelial neoplasia (AIN) grades 1, 2 and 3 (anal dysplasias and precancerous lesions) caused by HPV types 6, 11, 16 and 18, in males and females 9 through 26 years of age.

23 Dec 2010

Merck announces FDA Advisory Committee approval of GARDASIL for anal cancer and AIN treatment

Merck announced today that the U.S. Food and Drug Administration's (FDA) Vaccines and Related Biological Products Advisory Committee has advised that the data presented support an indication for GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant] for the prevention of anal cancer and anal intraepithelial neoplasia (AIN) in both males and females 9 through 26 years of age.

18 Nov 2010

Study may help develop preventative treatments for womb infections

Researchers funded by the Biotechnology and Biological Sciences Research Council (BBSRC) have established in mice the mechanism that detects and responds to the presence of bacteria in the womb a discovery that opens up the possibility of new preventative treatments for diseases like pelvic inflammatory disease and Chlamydia.

23 Sep 2010

Starpharma gets FDA nod to start phase 2 bacterial vaginosis study for VivaGel

Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) today announced it had received clearance from the US Food and Drug Administration (FDA) to commence a phase 2 study to investigate VivaGel® for the treatment of bacterial vaginosis (BV).

15 Jul 2010

Fear of having something in uterus deters teen girls from using intrauterine devices for birth control

Very few teenage girls in the United States use intrauterine devices for birth control, even though studies show they are safe, effective and extremely low-maintenance, according to researchers at Lucile Packard Children's Hospital and the Stanford School of Medicine.

9 Jul 2010

FDA grants Abbott 510(k) clearance to market molecular diagnostic test for detection of chlamydia, gonorrhea

Abbott announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration to market a new, sensitive molecular diagnostic test and instrument to simultaneously detect two of the nation's most prevalent sexually transmitted diseases (STDs), gonorrhea and chlamydia, including a new variant strain of chlamydia recently discovered in Sweden.

28 Jun 2010

Roche launches cobas(R) 4800 System in Canada for testing CT, NG and HPV

Roche Diagnostics Canada announced today the launch of a new Health Canada approved clinical laboratory system designed to increase laboratory testing efficiency and to accommodate current and long-term molecular diagnostic needs. The cobas(R) 4800 System combines in vitro diagnostic tests for Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG) and human papillomavirus (HPV) testing with fully-automated sample preparation and real-time polymerase chain reaction (PCR) technology.

From Roche Sequencing and Life Science 7 May 2010

Gonorrhea may soon become untreatable according to WHO

According to the World Health organization (WHO), gonorrhea may soon become untreatable and urgent measures need to be taken to prevent and treat the sexually transmitted infection. This is the result of improper use of first line antibiotics which has led to widespread anti microbial resistance to drugs. The cheaper antibiotics no longer have as much effect as they should and the higher antibiotics will soon lose efficacy as well.

30 Apr 2010

Changes in vaginal pH make women more susceptible to infections

Changes in vaginal pH as a result of common “pH triggers” make women more susceptible to infections such as bacterial vaginosis (BV). Understanding how the vaginal environment responds to pH fluctuation helps health professionals prevent and treat these conditions.

18 Feb 2010

Frequent chlamydia screening does not reduce infection in teenage girls

Frequent testing and treatment of infection does not reduce the prevalence of chlamydia in urban teenage girls, according to a long term study by Indiana University School of Medicine researchers published in the January 1, 2010 issue of the Journal of Infectious Diseases.

8 Jan 2010

Genocea Biosciences to develop Chlamydia trachomatis vaccine with UPMC grant

Genocea Biosciences, a leading vaccine discovery and development company, today announced it has been awarded a grant from the University of Pittsburgh Medical Center’s (UPMC) Sexually Transmitted Infections (STI) Cooperative Research Center for the development of vaccines for Chlamydia trachomatis.

15 Dec 2009

Roche launches new automated clinical laboratory system for HPV and CT/NG tests

Roche Molecular Systems, Inc. (SIX: RO, ROG; OTCQX: RHHBY) announced today the launch of a new clinical laboratory system designed to increase laboratory testing efficiency and to accommodate current and long-term molecular diagnostic needs.

10 Dec 2009

BD Diagnostics receives FDA clearance on Amplified DNA Assays

BD Diagnostics, a segment of BD (Becton, Dickinson and Company) (NYSE: BDX), announced today it has received clearance from the U.S. Food and Drug Administration (FDA) to utilize its BD ProbeTec(TM) Chlamydia trachomatis (CT) Qx and BD ProbeTec(TM) Neisseria gonorrhoeae (GC) Qx Amplified DNA Assays with samples collected during women's routine liquid-based Pap testing for cervical cancer screening.

From BD (Becton, Dickinson and Company) 8 Dec 2009

Economic crisis impacts health department capacity to address rising STD rates

Amid the mounting toll of budget cuts across the country, a new study from the National Coalition of STD Directors (NCSD) shows just how much an impact the economic crisis is having on sexually transmitted disease (STD) programs and in turn, having more broadly on public health infrastructure.

17 Nov 2009

Educational video induces girls diagnosed with PID to ensure partner treatment

A study at Johns Hopkins Children's Center found that girls diagnosed with pelvic inflammatory disease (PID) who watched a short educational video were three times more likely to discuss their condition with their partners and to ensure partner treatment than girls diagnosed and treated without seeing the film.

5 Nov 2009

$12.2 million grant from NIH for research on the sexually transmitted bacteria chlamydia

Perhaps the most comprehensive, multi-institutional study yet of the sexually transmitted bacteria chlamydia is under way at the University of Maryland, Baltimore (UMB).

29 Oct 2009

FDA approves Bayer's IUD Mirena for treating heavy menstrual bleeding

The U.S. Food and Drug Administration today approved Mirena (levonorgestrel intrauterine system) to treat heavy menstrual bleeding in women who use intrauterine contraception as their method of pregnancy prevention. This is the first intrauterine device approved by the FDA for this additional indication.

3 Oct 2009